University of Pavia.
University of Catania.
Acta Biomed. 2020 Jun 17;92(1):e2021003. doi: 10.23750/abm.v92i1.9948.
Background and aim Seasonal allergic rhinitis (SAR) is a common disease in childhood that is characterized by bothersome symptoms and impaired quality of life (QoL). As histamine is the pivotal pathogenic mediator in SAR, antihistamines are the first-line option in the treatment. Cetirizine is a well-known effective antihistamine. This real-life pilot study aimed to investigate the effectiveness of a 4-week continuous cetirizine treatment in a group of Italian children with SAR. Methods Total symptom score (TSS) and the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) were assessed at baseline and the end of the treatment. Results Cetirizine significantly improved QoL (in all domains) and symptom severity (p<0.001 for both). Conclusions The present preliminary study showed that a 4-week cetirizine treatment was able to improve QoL significantly. Cetirizine treatment also significantly reduced symptom severity in Italian children with SAR and was safe.
季节性过敏性鼻炎(SAR)是一种常见的儿童疾病,其特征是症状恼人和生活质量(QoL)受损。由于组胺是 SAR 的关键致病介质,因此抗组胺药是治疗的首选。西替利嗪是一种众所周知的有效抗组胺药。本真实生活试点研究旨在调查 SAR 意大利儿童群体中连续 4 周西替利嗪治疗的疗效。方法:在基线和治疗结束时评估总症状评分(TSS)和儿童鼻结膜炎生活质量问卷(PRQLQ)。结果:西替利嗪显著改善了生活质量(所有领域)和症状严重程度(均<0.001)。结论:本初步研究表明,4 周西替利嗪治疗可显著提高生活质量。西替利嗪治疗还显著降低了意大利 SAR 儿童的症状严重程度,且安全。